Why ALS Drug Research Struggles and How to Fix It

ALS is a rare but cruel disease that slowly shuts down the body while leaving the mind intact. Doctors have only approved three drugs for it since the mid-1990s, and none of them cure or stop the disease—they merely slow it down a little. Part of the problem is money. Running trials for ALS is extremely expensive, especially when researchers need many patients across multiple hospitals. Most early trials are too small to give clear answers, and lab models don’t reliably predict what will work in humans. Even with government pushes like the ALL ALS Act, too little cash flows to the large, long-term studies that could actually move the needle. Another issue is how research is set up. There are plenty of ALS databases and smaller networks, but they rarely talk to each other. Patients sign up in one place, researchers work in another, and funders move from idea to idea without a clear plan. This patchwork system wastes time and resources instead of building a steady pipeline of new ideas. Some promising treatments get lost because no one can afford to test them properly. Meanwhile, the few drugs that do get approved bring in revenue, but that money rarely flows back into the next round of research.Could things change? Yes—but only with smarter planning. One idea is to connect all the patient databases and trial sites into one big network. That way, finding enough volunteers for nationwide studies would become easier. Another idea is to use flexible trial designs that can adapt as results come in, so researchers aren’t stuck running outdated plans. Some groups suggest tying future funding to real milestones—like getting a drug past early safety tests—so investors only pay when there’s real progress. A bolder step: require companies that profit from approved ALS drugs to reinvest a slice of their earnings into new research. A unified, well-funded system wouldn’t just help ALS—it could show other rare brain diseases how to speed up their own searches for treatments.